- Global Pharma News & Resources

Global Hemoglobinopathies Market is projected to grow at a CAGR of 10.1% during the forecast period 2020-2027

A new research report published by Fior Markets with the title Hemoglobinopathies Market by Type (Sickle Cell Disease, Thalassemia, Others), Diagnosis (Genetic Testing, Red Blood Cell (RBC) Count Test, Hemoglobin Isoelectric (Hb IEF) Focusing, Hemoglobin By High Performance Liquid Chromatography (HPLC) Test, Hemoglobin Solubility Test, Hemoglobin Electrophoresis (Hb ELP) Test), Therapy (Blood Transfusion, Bone Marrow Transplant, Iron Chelation Therapy, Others), Regions, and Global Forecast 2020-2027.

The global hemoglobinopathies market is expected to grow from USD 6.35 billion in 2019 to USD 13.72 billion by 2027, at a CAGR of 10.1% during the forecast period 2020-2027. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period 2020-2027. This growth is due to factors like developing healthcare infrastructure, unmet clinical needs, rising patient awareness levels, and the introduction of low-cost, indigenously-manufactured diagnostic kits for sickle cell disease & thalassemia. On the other hand, the North America region accounted for the major market share of 45.25% in the year 2019 and is anticipated to grow throughout the projected period. The large share of this segment is attributed to key factors such as rising awareness among patients & healthcare professionals regarding hemoglobinopathies-related genetic testing, supportive government programs, increasing prevalence of blood disorders, presence of advanced healthcare infrastructure, good reimbursement scenario, and increasing R&D investments by major players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


Key players in the global hemoglobinopathies market are Alnylam Pharmaceuticals, Gamida Cell, Sanofi, Global Blood Therapeutics, Sangamo Therapeutics Inc., bluebird bio Inc., Prolong Pharmaceuticals, Celgene Corporation, and Emmaus Life Sciences Inc., among others. Key companies are mainly focusing on developing new products, forming partnerships, and joint ventures to gain significant market share in the global hemoglobinopathies market.

The type segment includes sickle cell disease, thalassemia, and others. Sickle cell disease dominated the market and held the largest market share of 38.4% in the year 2019. This segment is also expected to expand at a significant CAGR during the forecast period. The diagnosis segment includes genetic testing, red blood cell (RBC) count test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin by high performance liquid chromatography (HPLC) test, hemoglobin solubility test, and hemoglobin electrophoresis (Hb ELP) test). The red blood cell (RBC) count test is the most commonly used first-line screening method. Red blood cell (RBC) count test segment dominated the market and valued at USD 1.2 billion in the year 2019. The therapy segment includes blood transfusion, bone marrow transplant, iron chelation therapy, and others. Blood transfusion dominated the market and held the largest market share of 29.3% in the year 2019. The large share of this segment is attributed to factors like its high success rate & acceptance, and rising government initiatives for increasing blood donations.


About the report:
The global hemoglobinopathies market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 23-Sep-2020